Updated from 2:27 p.m. EDT
Pharmaceutical Product Development
( PPDI) were among the best-performing health-related stocks Tuesday, soaring 21% after the drug company posted in-line first-quarter earnings on better-than-expected revenue.
The company earned $41.8 million, or 35 cents a share, on revenue of $299.4 million. Analysts polled by Thomson First Call expected earnings of 35 cents a share and revenue of $274.8 million. In last year's first quarter, the company earned $32.9 million, or 29 cents a share, on revenue of $244.1 million.
"In a quarter that has been historically light, PPD delivered its second-largest quarter of gross and net new business on record, as well as year-over-year margin expansion in the development segment," the company said. Shares were trading up $7.02 to $40.63.
rose 8% after the health-information company previewed better-than-expected first-quarter results. The company sees earnings before interest, taxes, non-cash and other items of 18 cents a share, up from an earlier view of 14 cents to 15 cents a share. The company now predicts revenue of $338 million to $339 million, up from its earlier forecast of $328 million to $338 million. Analysts project earnings of 15 cents a share on revenue of $329.6 million. The company attributed the better-than-expected outlook to a host of items, including stronger medical claims volume at its Emdeon business services unit.
For all of 2006, Emdeon raised its adjusted EBITDA forecast to $225 million to $255 million from an earlier view of $200 million to $230 million. The company now sees revenue of $1.38 billion to $1.43 billion, up from an earlier prediction of $1.37 billion to $1.42 billion. The company plans to issue its financial results on May 4. Shares were trading up 87 cents to $11.43.
posted first-quarter results that beat expectations and issued a second-quarter sales guidance that topped forecasts, sending shares up 10%. The medical-device company reported a first-quarter loss of $855,000, or 6 cents a share, on revenue of $10 million. Analysts expected a bigger loss of 10 cents a share and revenue of $9.3 million. During the year-ago period, the company recorded a loss of $289,000, or 2 cents a share, on revenue of $7.3 million.
Looking ahead, Vascular Solutions projects second-quarter revenue of $10.4 million to $10.7 million. Analysts project revenue of $10.1 million. Shares were trading up 79 cents to $8.67.
rose 1% after the company licensed its HIV drug to drug developer ImQuest Pharmaceuticals. ImQuest plans to develop ISIS 5320 as a topical microbicide treatment aimed at preventing the sexual transmission of HIV.
"Licensing ISIS 5320 to ImQuest will allow us to benefit from ImQuest's expertise and highly focused research efforts in anti-HIV therapeutics, while ImQuest will benefit from our experience in oligonucleotide drug development and access to our intellectual property," Isis said in a statement. ImQuest will be responsible for the clinical development and commercialization of the drug. Isis, meanwhile, will receive royalties tied to product sales. Isis shares were up 11 cents to $7.76.
fell 8% after the maker of insecticides and organic fertilizer reaffirmed its 2006 guidance and announced that its chief executive is taking a temporary leave of absence. The company also said its second-quarter product sales are on target. In late March, the company projected "substantial" year-over-year sales growth on gross margin of about 30%.
Bodisen said that its CEO, Karen Qiong Wang, would take a temporary leave of absence so that she could get a medical check-up that's related to a surgery that was performed late last year. During Wang's short absence, President Bo Chen will lead the company.
As for the company's recently completed first quarter, Bodisen said that it expects to post record earnings when it issues its financial results during the next month. Shares were trading down $1.40 to $15.32.
( RSCR) rose 5% after the company agreed to acquire Armstrong Uniserve, a Tacoma, Wash.-based in-home personal care and respite services company. ResCare, which provides services to people with disabilities and other special needs, said the deal is expected to add $28 million in annual sales.
"AUI will provide ResCare with a substantial presence in Washington and provide an opportunity for continued growth in these much needed services," ResCare said. The price of the Armstrong acquisition, which is expected to close in May, wasn't disclosed. Shares of ResCare were trading up 90 cents to $19.84.
Other health care volume movers included
, down $1.36 to $50.31;
, up 25 cents to $24.69;
, up 33 cents to $21.81;
, down 45 cents to $49.11;
Johnson & Johnson
, up 9 cents to $57.74;
, up 95 cents to $70.35;
, up 40 cents to $34.20;
, up 21 cents to $24.66; and
( SGP), up 14 cents to $18.39.